Karyopharm’s attempt to expand selinexor (Xpovio) into endometrial cancer landed another major setback as the company’s phase 3 XPORT-EC-042 trial missed its progression-free survival primary endpoint. The result dealt a sharper blow given the program’s cash runway constraints and the company’s need to maintain strategic flexibility. After reporting cash of $91.2 million as of Q1, Karyopharm said it expected to fund operations through the latter part of Q3, while exploring additional financings and strategic alternatives. Even with plans to submit an sNDA in August for an accelerated approval request in myelofibrosis (in combination with Jakafi), the endometrial readout drove substantial share declines. The update highlights the financing fragility that often follows late-stage translational failures, especially for companies reliant on pipeline-in-a-product narratives across multiple tumor types.